COVID-19 Resource Center
COVID-19 Resource Center
Perspective from Paul M. Ridker, MD, MPH
Source:

Press Release

Disclosures: COLCORONA was funded by the government of Quebec, the NHLBI/NIH, Montreal philanthropist Sophie Desmarais and the COVID-19 Therapeutics Accelerator, an initiative launched by the Bill and Melinda Gates Foundation, Wellcome and Mastercard. CGI, Dacima and Pharmascience of Montreal were also collaborators in the trial. Tardif reports no relevant financial disclosures.
January 25, 2021
1 min read
Save

COLCORONA topline results: Colchicine reduces hospitalization, death in COVID-19

Perspective from Paul M. Ridker, MD, MPH
Source:

Press Release

Disclosures: COLCORONA was funded by the government of Quebec, the NHLBI/NIH, Montreal philanthropist Sophie Desmarais and the COVID-19 Therapeutics Accelerator, an initiative launched by the Bill and Melinda Gates Foundation, Wellcome and Mastercard. CGI, Dacima and Pharmascience of Montreal were also collaborators in the trial. Tardif reports no relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Colchicine reduced hospitalization and mortality in patients with COVID-19 by more than 20%, according to topline results of the COLCORONA randomized trial.

According to a press release from the Montreal Heart Institute, the COLCORONA trial indicates colchicine, an anti-inflammatory drug primarily used to treat gout, could prevent cytokine storm and other complications in patients with COVID-19 compared with placebo.

Source: Adobe Stock

Treating higher-risk patients with colchicine as soon as a confirmed COVID-19 diagnosis reduced risk for developing a severe form of the disease and subsequently lowered the number of hospitalizations, according to the release.

For the contactless, randomized, double-blind, placebo-controlled trial, researchers in Canada, U.S., Europe, South America and South Africa evaluated the efficacy of colchicine in lowering risk for severe complications associated with COVID-19. COLCORONA included approximately 4,488 patients with COVID-19 and at least one other risk factor for COVID-19 complications, who were not hospitalized at the time of enrollment.

In the overall cohort, colchicine reduced death or hospitalization by 21% compared with placebo, a result that “approached statistical significance,” according to the release.

In an analysis of 4,159 patients who had a confirmed COVID-19 diagnosis from a nasopharyngeal PCR test, compared with placebo, colchicine reduced hospitalizations by 25%, the need for mechanical ventilation by 50% and mortality by 44%, and these results were statistically significant, according to the release.

Jean-Claude Tardif

“Our research shows the efficacy of colchicine treatment in preventing the ‘cytokine storm’ phenomenon and reducing the complications associated with COVID-19,” Jean-Claude Tardif, MD, director of the Montreal Heart Institute Research Center and professor of medicine at the Université de Montréal, said in the release. “We are pleased to offer the first oral medication in the world whose use could have a significant impact on public health and potentially prevent COVID-19 complications for millions of patients.”

As Healio previously reported, colchicine has also been shown to reduce CVD risk in high-risk patients from the COLCOT and LoDoCo2 trials.